Neurizon Therapeutics Limited has released a press release.
Appendix 4C & Company Update - Sep 2018
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Develops GMP Method for Monepantel Analogues
- PharmAust Progresses Monepantel Tablet Program for Cancer
- Olivia Newton-John Cancer Reseach Institute collaboration
- Reformulation of MPL into tablet form for upcoming trials
- Appendix 4C & Company Update - June 18
Later from Neurizon Therapeutics
- GMP Tablet Manufacture Commences for Canine Clinical Trials
- PharmAust Develops Method for MPL/Analogue Manufacture
- Monepantel Principal Metabolite Shows Anti-Cancer Activity
- Optimisation of Monepantel Uptake
- PharmAust and Elanco Execute Data Sharing Agreement
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics